Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in COVID-19
NCT04348500Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in coronavirus disease 2019 (COVID-19), sponsored by Cedars-Sinai Medical Center. Started Apr 2020; status: completed.
02
Drugs
clazakizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04348500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348500.